A5040625301- COVID-19 Clinical Research Studies
- Venous Thromboembolism Diagnosis and Management
- SARS-CoV-2 and COVID-19 Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Atrial Fibrillation Management and Outcomes
- COVID-19 and healthcare impacts
- Blood Coagulation and Thrombosis Mechanisms
- Long-Term Effects of COVID-19
- Hemophilia Treatment and Research
- Acute Ischemic Stroke Management
- Antifungal resistance and susceptibility
- Vitamin K Research Studies
- Adipokines, Inflammation, and Metabolic Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Platelet Disorders and Treatments
- Central Venous Catheters and Hemodialysis
- Research on Leishmaniasis Studies
- Pneumonia and Respiratory Infections
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Nail Diseases and Treatments
- Complement system in diseases
- Neurological Disorders and Treatments
- Peripheral Nerve Disorders
- Cardiovascular Effects of Exercise
- Nerve Injury and Rehabilitation
KU Leuven
2017-2024
Hospital Universitari Germans Trias i Pujol
2020-2022
Universidad Católica San Antonio de Murcia
2022
Universitat Autònoma de Barcelona
2020-2022
Universitair Ziekenhuis Leuven
2019-2022
Background Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with severe acute respiratory syndrome 2 (SARS-CoV-2) neutralising antibody titres, at time-points and severities of illness. Methods In the prospective multicentre DAWn-plasma trial, adult patients hospitalised COVID-19 were to 4 units open-label combined standard care (intervention group) or alone (control group). Plasma from donors titres (50%...
Emicizumab is approved to prevent bleeding in patients with congenital haemophilia A or without inhibitors. However, no randomized trials addressed the efficacy of emicizumab acquired (AHA).To report clinical and biochemical response AHA.This single-centre retrospective study included seven adults AHA between November 2020 May 2022. We collected patient characteristics, laboratory coagulation parameters, use haemostatic agents, bleeds thrombotic events. Treatment was monitored using...
The peak of the global COVID-19 pandemic has not yet been reached, and many countries face prospect a second wave infections before effective vaccinations will be available. After an initial phase viral replication, some patients develop illness in which host thrombotic inflammatory responses seem to drive complications. Severe disease is linked high mortality, hyperinflammation, remarkably incidence events. We hypothesize crucial pathophysiological role for contact pathway coagulation...
Factor XI is almost dispensable for haemostasis, but its role in thrombosis has become increasingly clear. Targeting factor could potentially prevent with little or no effect on haemostasis. This review explains the underlying mechanisms of and haemostasis elucidates rationale inhibitors based pathophysiology epidemiological pre-clinical data. It further outlines different modes inhibition. Finally, article provides an overview current clinical evidence ongoing trials various indications.
Anticoagulant therapy has always been tightly connected with bleeding risk, as two sides of the same coin. New insights in thrombosis and hemostasis prompted development intrinsic pathway inhibitors that promise to uncouple hemostasis. Treating preventing thrombotic complications without associated risk opens up many new possibilities for patients an unmet need current anticoagulant drugs. Many candidate drugs are being investigated phase I, II, III clinical trials. In this review, we will...
Venous thromboembolism (VTE) frequently occurs in hospitalized patients with coronavirus disease 2019 (COVID-19). The optimal dose of anticoagulation for thromboprophylaxis COVID-19 is unknown.
Azithromycin was rapidly adopted as a repurposed drug to treat coronavirus disease 2019 (COVID-19) early in the pandemic. We aimed evaluate its efficacy patients hospitalised for COVID-19.In series of randomised, open-label, phase 2 proof-of-concept, multicentre clinical trials (Direct Antivirals Working against novel (DAWn)), several treatments were compared with standard care. In 15 Belgian hospitals, moderate severe COVID-19 allocated 2:1 receive care plus azithromycin or alone. The...
Thromboinflammation plays a central role in severe COVID-19. The kallikrein pathway activates both inflammatory pathways and contact-mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes hospitalized COVID-19 patients.In this multicenter open-label randomized clinical trial (EudraCT 2020-001739-28), patients with were 1:2 to receive standard care (SOC) or SOC plus study intervention. intervention consisted aprotinin (2,000,000 IE IV four...
ECG abnormalities in COVID-19 have been widely reported, however data after discharge is limited. The aim was to describe on admission and following recovery of COVID-19, their associated mortality.All patients hospitalized a tertiary care hospital between March 7th July 1st 2020 with were included retrospective registry. first collected, together an the absence acute pathology. Automated measures clinical interpretations collected. Multivariate Cox regression analysis performed predict...
Abstract Background Bleeding is a main cause of morbidity and mortality in critically ill cardiogenic shock patients, supported by short-term percutaneous mechanical circulatory support (pMCS) devices. not only occurs because obligatory heparin antiplatelet therapy (both required the prevention pump stent thrombosis) but possibly also results from device-related coagulopathy. Similar to long-term ventricular assist devices, shear-induced acquired von Willebrand syndrome (AVWS) might further...
An amendment to this paper has been published and can be accessed via the original article.
Abstract Background The peak of the global COVID-19 pandemic has not yet been reached and many countries face prospect a second wave infections before effective vaccinations will be available. After an initial phase viral replication, some patients develop illness in which host thrombotic inflammatory responses seems to drive complications. Severe disease is linked high mortality, hyperinflammation, remarkably incidence events. We hypothesize crucial pathophysiological role for contact...
Background: Drug repurposing is an attractive strategy to rapidly develop affordable therapy against COVID-19. The antifungal drug itraconazole exerts in vitro activity SARS-CoV-2 comparable that of hydroxychloroquine. Preclinical and clinical studies are required investigate if effective for the treatment and/or prevention Methods: Due initial absence preclinical models effect was explored a clinical, proof-of-concept, open-label, single-center study, which hospitalized patients with...
Abstract Introduction Contact of blood with artificial surfaces such as mechanical support devices, catheters, and heart valves activates the contact activation (CA) pathway coagulation. Furthermore, recent animal data clinical studies suggest a more important contribution CA in pathological thrombus formation other cardiovascular diseases. Direct oral anticoagulants (DOACs) are recommended first-line treatment most patients who require long-term anticoagulation. However, because DOACs...